Cited by 303Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsAlcohol Consumption and Health Effects

The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

Le, Michael H., Le, David M., Baez, Thomas C., Wu, Yuankai, Ito, Takanori, Lee, Eunice Y., Lee, KeeSeok, Stave, Christopher D., Henry, Linda, Barnett, Scott D., Cheung, Ramsey, Nguyen, Mindie H.·2023·Journal of Hepatology

DOI 10.1016/j.jhep.2023.03.040

Open this paper in CoChat — free account

Abstract

Background & aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. We aimed to estimate the pooled global NAFLD incidence.Methods We performed a systematic review and meta-analysis of cohort studies of adults without NAFLD at baseline to evaluate the global incidence of ultrasound-diagnosed NAFLD.Results A total of 63 eligible studies (1,201,807 persons) were analyzed. Studies were from Mainland China/Hong Kong (n = 26), South Korea (n = 22), Japan (n = 14), other (n = 2, Sri Lanka, Israel); 63.8% were clinical center studies; median study year 2000 to 2016; 87% were good quality. Among the 1,201,807 persons at risk, 242,568 persons developed NAFLD, with an incidence rate of 4,612.8 (95% CI 3,931.5-5,294.2) per 100,000 person-years and no statistically significant differences by study sample size (p = 0.90) or study setting (p = 0.055). Males had higher incidence vs. females (5,943.8 vs. 3,671.7, p = 0.0013). Both the obese (vs. non-obese) and the overweight/obese groups (vs. normal weight) were about threefold more likely to develop NAFLD (8,669.6 vs. 2,963.9 and 8,416.6 vs. 3,358.2, respectively) (both p <0.0001). Smokers had higher incidence than non-smokers (8,043.2 vs. 4,689.7, p = 0.046). By meta-regression, adjusting for study year, study setting, and study location, study period of 2010 or after and study setting were associated with increased incidence (p = 0.010 and p = 0.055, respectively). By country, China had a higher NAFLD incidence compared to non-China regions (p = 0.012) and Japan a lower incidence compared to non-Japan regions (p = 0.005).Conclusions NAFLD incidence is increasing with a current estimate of 4,613 new cases per 100,000 person-years. Males and overweight/obese individuals had significantly higher incidence rates compared to females and those of normal weight. Public health interventions for prevention of NAFLD are needed with a special emphasis on males, overweight/obese individuals, and higher risk regions.Impact and implications Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of people worldwide and appears to be increasing, but data to estimate the incidence rate are limited. In this meta-analytic study of over 1.2 million people, we estimated an incidence rate of NAFLD of 46.13 per 1,000 person-years with significant differences by sex, BMI, geography, and time-period. As treatment options for NAFLD remain limited, prevention of NAFLD should remain the focus of public health strategies. Studies such as these can help policy makers in determining which and whether their interventions are impactful.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2023.03.040

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Untitled work
(2014) · Medical Entomology and Zoology · Cited by 17,633
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citation
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method
IntHout, J., Ioannidis, J. P., & Borm, G. F. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-25 · Cited by 2,419
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Non-alcoholic fatty liver disease - a global public health perspective
Younossi, Z. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.033 · Cited by 2,149
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
Estes, C., Anstee, Q. M., Arias, M., Bantel, H., Bellentani, S., Caballería, J., Colombo, M., Craxì, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 2,046
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., et al. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30077-7 · Cited by 925

Show all 51 references

Sorted by citations

Items 201–300 of 302

Clinical potential of undercarboxylated osteocalcin in metabolic and neurodegenerative diseases: From biomarker to therapeutic target
Ding, Y., Yang, Y., Sun, L., Liu, J., & Tao, B. (2025) · LabMed discovery. · doi:10.1016/j.lmd.2025.100074 · Cited by 1
Dietary manganese intake is positively associated with metabolic dysfunction-associated steatotic liver disease: a multicohort study
Yu, H., Wang, D., Yan, Y., Jiao, L., Zhang, J., Gu, Y., Zhang, S., Zhang, Q., Liu, L., Ge, M., et al. (2025) · European Journal of Nutrition · doi:10.1007/s00394-025-03708-8 · Cited by 1
“Specifically, notably age and gender, given the established correlation between dietary Mn intake and gender [27–29].”
Correlation between PLT, MPV, PDW and liver fibrosis and inflammatory activity in patients with NAFLD: A retrospective case-control study
Zhang, Z., & Wang, J. (2025) · Medicine · doi:10.1097/md.0000000000043815 · Cited by 1
“[8] Currently, liver biopsy remains the gold standard for evaluating liver fibrosis and inflammatory activity.”
Identifying novel therapeutic targets for non-alcoholic fatty liver disease using bioinformatics approaches: from drug repositioning to traditional Chinese medicine
Zhang, J., Meng, T., Gao, W., Li, X., & Xu, J. (2025) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2025.1613985 · Cited by 1
“Most patients with NAFLD remain asymptomatic; however, individuals progressing to metabolic-associated steatohepatitis may experience symptoms such as fatigue, malaise, and vague discomfort in the right upper quadrant (Younossi et al., 2011; Le et al., 2023).”
Age and sex differences in intrapancreatic fat deposition: A cross-sectional CT study
Zhang, Y., Zhang, D., Wang, R., Yu, R., Yu, W., Wang, J., & Chen, X. (2026) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2026.102770 · Cited by 1
Data-driven classification of metabolic-associated steatotic liver disease subtypes predicting hepatic and extrahepatic progression
Fang, D., Li, S., Lu, J., Zhou, W., Bi, Y., Shi, Y., & Gu, T. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003984 · Cited by 1
“[1] The situation is particularly severe in China, representing a major public health challenge.”
Exercise and dietary interventions ameliorate MASLD via the hepatic PPARγ-miR-802-Psmd2 axis
Liu, Y., Liu, J., Song, P., Sun, L., Fang, Z., Yue, Z. H., Duan, J., He, F., & Wang, L. (2026) · eGastroenterology · doi:10.1136/egastro-2025-100334 · Cited by 1
Yinchenhao Decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial
Xu, F.-P., Yang, C., Yu, S., Cai, H., Hui, M.-Y., Fang, L., Chen, G., Jiang, S., Qi, S.-L., Wu, S.-J., et al. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.03.003 · Cited by 2
Differential Mortality Risk by Age in Males and Females With Steatotic Liver Disease
Yan, T., Chien, N., Nguyen, V. H., Le, I., Gudapati, S. T., Chau, A., Zhang, X., Barnett, S. D., Linden, S., Henry, L. L., et al. (2026) · MedComm · doi:10.1002/mco2.70677 · Cited by 1
Fasting blood glucose to high-density lipoprotein cholesterol ratio and MASLD risk: non-linear association and BMI mediation in non-diabetic adults
Xuan, Y., Wu, D., & Yao, Q. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1818931 · Cited by 1
“Over the past three decades, its global prevalence has overtaken that of chronic viral hepatitis and alcoholic liver disease—underscoring an urgent need for optimized screening and risk stratification strategies (6–9).”
Unveiling novel macrophage-specific biomarkers in MASH through single-cell sequencing for diagnostic modeling
Wang, T., Zhu, X., Zhang, Y., Su, L., & Pan, T. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101048 · Cited by 1
“MASH represents a critical progressive phenotype, with up to 39% of the patients developing cirrhosis within 10 – 15 years (1, 2).”
Multidimensional Phenotyping of the OB-DIGITHUM Cohort of 1,014 Adults with Obesity across Four Sex- and Age-Stratified Profiles
Vázquez, C., Álvarez, T. M., Cárdenas‐Salas, J., Luca, B. L., Paniagua, A., Fernández, Y., Pozo, V. P. D. A., Marijuan, C., de Arrieta, F., Causso, C., et al. (2026) · Obesity Facts · doi:10.1159/000552187 · Cited by 1
“NAFLD prevalence increased with age in women, but remained lower than in men, consistent with prior data Sex-and Age-Specific Obesity Phenotypes Obes Facts DOI: 10.1159/000552187 [33, 34].”
Influential
The Potential Alleviating Property Against NAFLD by Ganoderma lucidum With Bacteria‐Enzyme Synergistic Fermentation
Sun, M., Li, K., Wang, Z., Dai, J., Mao, J., Cai, M., & Sha, R. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71981 · Cited by 1
“NAFLD is strongly linked to dysregulated lipid metabolism and elevated oxidative stress (Liang et al. 2022), and its global prevalence has been steadily increasing, posing a growing public health burden (Le et al. 2023).”
Digital Pathology–Enabled Artificial Intelligence for Fibrosis Assessment in Metabolic Dysfunction–Associated Steatohepatitis: Needs, Current Progress, and Barriers
Rastogi, A. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103608 · Cited by 1
Jiawei Taohe Chengqi decoction alleviates angiogenesis associated with LECT2/CD209-mediated macrophage reprogramming in hepatic fibrosis
He, Y., Huang, J., Liang, X., Ye, L., Shao, C., Lan, W., Ding, Y., & Zhang, J. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158657 · Cited by 1
The Global Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease: Regional Hotspots, Trends, and Future Projections
Alqahtani, S. A., Buckholz, A., & Schneider, C. V. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00746-6 · Cited by 1
“Globally, across 63 cohort studies comprising > 1.2 million adults without steatosis at baseline, > 240,000 incident cases were identified using NAFLD-era diagnostic criteria [ 14].”
Influential
Thyroid hormone receptor-β agonist simedeutirom (HSK31679) for Chinese patients with metabolic dysfunction-associated steatohepatitis: a 52-week, multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
Xue, F., Liu, J., Chen, J., Li, X., 王思奎, Luo, Y., Zhang, B., Geng, J., Wang, W., Zhao, R., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00243-8 · Cited by 1
Evaluating the relative importance of different blood pressure indices in screening for NAFLD: a survey report based on a health examination population
Hu, C., Yu, Z., Wei, C., Sheng, G., Chen, J., & Zou, Y. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1338156 · Cited by 1
Hyperhomocysteinaemia and MASLD: Causal relationship or spurious correlation?
van Sloten, T. T., Brouwer, W. P., Runge, J. H., & van Erpecum, K. J. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.10.021 · Cited by 1
Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) from a Young Age Due to a Rare Genetic Disorder, Familial Partial Lipodystrophy: A Case Report and Review of the Literature
Vorona, E., Sorkina, E., & Trebicka, J. (2024) · Livers · doi:10.3390/livers4040047 · Cited by 1
“Metabolic dysfunction-associated steatotic liver disease is a common condition in the general population with the estimated prevalence up to 30% [15–17].”
Prevalence of Nonalcoholic Fatty Liver Disease among Obese Patients Presented in Liaquat University Hospital Hyderabad/Jamshoro
Memon, Y., Fareed, G., Shaikh, T. Z., Qureshi, K. A., Karim, I., & Memon, Z. H. (2025) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v6i1.2165 · Cited by 1
Urinary biomarkers of drinking water disinfection byproducts in relation to blood-based liver function parameters among reproductive-aged Chinese women
Gui, P.-P., Deng, Y.-L., Zhang, M., Yu, M., Liu, P., Zeng, J.-Y., Wu, Y. Q., Li, C.-R., Liu, X., Li, Y.-J., et al. (2025) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2025.179016 · Cited by 1
DIAGNOSTIC VALUE OF NITROGEN METABOLISM DISORDERS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN COMORBID PATIENTS WITH METABOLIC SYNDROME AND STRATIFICATION OF DISEASE STAGES
Арямкина, О. Л., Biek, A. U., & Saitov, A. R. (2023) · Ulyanovsk Medico-biological Journal · doi:10.34014/2227-1848-2023-3-49-66 · Cited by 1
Defining characteristics and outcomes for patients with non-alcoholic fatty liver disease admitted to hospital with decompensated cirrhosis
Tavabie, O. D., Abbott, J., Abeysekera, K. W. M., Balachandrakumar, V. K., Bennett, K., Brennan, P., Buchanan, R. M., Dhaliwal, A., Galanakis, V., Hardy, T., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.035 · Cited by 1
Fatty Acid Esterification as a NASH Therapeutic Target
Sakuma, I., & Vatner, D. F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.10.011 · Cited by 1
Chronic Hepatitis B and Steatotic Liver Disease: A Blessing in Disguise?
Xu, X., Nguyen, M. H., & Li, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.11.039 · Cited by 1
Topological Deep Learning: A New Dimension in Gastroenterology for Metabolic Dysfunction-Associated Fatty Liver
Singh, Y., Ammar, R., & Shehata, M. A. (2024) · Cureus · doi:10.7759/cureus.60532 · Cited by 1
“MASLD is now the most common liver disease globally, with an estimated prevalence of 32%, and is a primary cause of liver-related morbidity and mortality [1,2].”
Background
Interleukin-mediated therapies in liver diseases and comorbidity effects
Bouare, N., & Delwaide, J. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i7.980 · Cited by 1
Chronic pharmacologic manipulation of dopamine transmission ameliorates metabolic disturbance in syndrome caused by mutated trappc9Preprint
Li, Y., Usman, M., Sapp, E., Ke, Y., Wang, Z., Boudi, A., DiFiglia, M., & Li, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.13.580023
Research Progress on Co-Pathogenesis of Non-Alcoholic Fatty Liver Disease and Sarcopenia
杨, 国. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441210
Associations between Systemic Inflammatory Biomarkers and Metabolic Dysfunction Associated Steatotic Liver Disease: Findings from NHANESPreprint
Qiu, X., Shen, S., Lu, D., Jiang, N., Feng, Y., Li, J., Yang, C., & Xiang, B. (2024) · Research Square · doi:10.21203/rs.3.rs-4346138/v1
Liver Stiffness, Liver Function and Subsequent Metabolic Syndrome in NAFLD Associated Subclinical Atherosclerosis: Perspective from Mediation AnalysisPreprint
Qu, Y., Liu, J., Xing, C., & Yuan, L. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4826078
Association between type 2 diabetes mellitus complications and NAFLD: Insights from the NHANES 2017-2020 and Mendelian randomization studyPreprint
Wan, S., Li, M., Lu, S., Zhai, Z., Wu, Y., & Gong, W. (2024) · Research Square · doi:10.21203/rs.3.rs-4760695/v1
Identification of protein partners for small molecules reshapes the understanding of nonalcoholic steatohepatitis and drug discovery
Wang, D., & Wang, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123031
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in ratsPreprint
Yang, H., Zhang, C., Kim, W., Shi, M., Kılıçlıoğlu, M., Bayram, C., Bolat, İ., Tozlu, Ö. Ö., Baba, C., Yuksel, N., et al. (2024) · eLife · doi:10.7554/elife.98427.1
Ethanol extract of cassia seed alleviates metabolic dysfunction-associated steatotic liver disease by acting on multiple lipid metabolism-related pathways
Li, W., Wang, J., Yang, Y., Duan, C., Shao, B., Zhang, M., Wang, J., Li, P., Yuan, Y., Zhang, Y., et al. (2024) · Frigid Zone Medicine · doi:10.1515/fzm-2024-0017
Cirrhose métabolique : une entité en plein essor
Ratziu, V. (2024) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2024.11.012
The Role of Gut Microbiota in Metabolic Dysfunction-Associated Fatty Liver Disease (MASLD)
Bucurica, S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1008148
НАТРІЙУРЕТИЧНИЙ ПЕПТИД – РАННІЙ МАРКЕР УРАЖЕННЯ НИРОК У ХВОРИХ ПРИ НЕСПЕЦИФІЧНОМУ ВИРАЗКОВОМУ КОЛІТІ ТА СИНДРОМІ ПОДРАЗНЕНОЇ ТОВСТОЇ КИШКИ У ПОЄДНАННІ З НЕАЛКОГОЛЬНОЮ ЖИРОВОЮ ХВОРОБОЮ ПЕЧІНКИ
Сірчак, Є. С., Корнаш, В. В., & Устич, О. В. (2024) · Здобутки клінічної і експериментальної медицини · doi:10.11603/1811-2471.2024.v.i4.15017
Characterizing Nonalcoholic Fatty Liver Disease (NAFLD) in Lean Individuals at a Tertiary Care Hospital: A Cross-sectional Study
Abbas, Z., Nazir, S., Maqbool, S., Kumar, M., Gazder, D. P., & Samejo, S. A. (2024) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1452
The Changing Pathogenesis of Liver Cancer in Hawaii over Three Decades
Wong, L. L., Hromalik, L. R., Hernandez, B. Y., Acoba, J. D., & Kwee, S. A. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1399
Prevalence of advanced hepatic fibrosis and individualization of associated risk factors by Bayesian analysis in MASLD patients in French cardio-metabolic health networks
Doffoël, M., Chaffraix, F., Chahard, A., Gras, D., Bonomi, O., Bildstein, C., Tripon, S., Royant, M., & Meyer, N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316158
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in ratsPreprint
Yang, H., Zhang, C., Kim, W., Shi, M., Kılıçlıoğlu, M., Bayram, C., Bolat, İ., Tozlu, Ö. Ö., Baba, C., Yuksel, N., et al. (2025) · eLife · doi:10.7554/elife.98427.2 · Cited by 1
Hepatic steatosis development as a long-term complication among testicular germ cell tumor survivors
Akkuş, E., Karaosmanoğlu, A. D., Gülpınar, B., Süer, E., & Ürün, Y. (2025) · Future Oncology · doi:10.1080/14796694.2025.2467613
Potential association of neutrophil-albumin ratio with non-alcoholic fatty liver disease: A cross-sectional study based on NHANES
Xiang, F., Mao, H.-X., Xu, Y., & Ge, X.-X. (2025) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v33.i2.122
Comorbidities related to metachronous recurrence for early gastric cancer in elderly patients
Xiang, Y., Yuan, Y., Wang, Z., Zhu, Y., Li, W., Ye, Q.-G., Wang, Y., Sun, Q., Ding, X., Longi, F., et al. (2025) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v17.i3.99540
Investigation of Inflammation Rates (Neutrophil/Lymphocyte) and Hemogram Results in the Stages of Non-Alcoholic Fatty Liver Disease
Gül, M. A., Tozcu, D., & Çapraz, M. (2025) · Meandros Medical And Dental Journal · doi:10.69601/meandrosmdj.1614618
GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD)
Pagès, L., Martí‐Carretero, A., Rojo, D., Sabiote, C., Faninam, F., Parks, S. C., Martínez-Gómez, M., Cusidó, M. S., Akhlaghi, N., Muñoz, S., et al. (2025) · Current Hepatology Reports · doi:10.1007/s11901-025-00692-9 · Cited by 1
“MASLD current estimated global prevalence is above 30% with South America and Middle East as the regions where higher rates are recorded [1, 2].”
AGE-RELATED FEATURES OF LIVER CHANGES DURING INTERMITTENT FASTING (LITERATURE REVIEW)
Kryvozub, D., Riabenko, T. V., & Ponyrko, A. (2025) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2025;13(2):352-363
Association between the Dietary Inflammatory Index and Metabolic Dysfunction-Associated Fatty Liver Disease and Hepatic Fibrosis: A Cross-sectional Analysis using NHANES 2017-2020Preprint
Chen, Y., Lai, Y., Ou, S., Xie, Y., & Cheng, Q. (2025) · Research Square · doi:10.21203/rs.3.rs-7048643/v1
Management of asymptomatic patients with abnormal liver function tests
Gabeta, S., Dalekos, G. Ν., & Gatselis, N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.025
Genetic determinants of hepatocellular carcinoma: role of PNPLA3, FABP2, FADS1/FADS2 genes in Yakuts
Pavlova, N. I., Krylov, A. V., Bochurov, A. A., Troev, I. P., & Алексеевич, К. Х. (2025) · Russian Journal of Oncology · doi:10.17816/onco643393
Hard Sample Mining-Based Tongue Diagnosis for Fatty Liver Disease Severity Classification
Chen, T., Gao, J., Yong, X., Qiu, W., Wu, Y., Ye, W., & Liu, K. (2025) · Lecture notes in computer science · doi:10.1007/978-3-032-05182-0_26
Air pollution: A new avenue for a population-level approach to tackle metabolic dysfunction-associated steatotic liver disease (MASLD)?
van Erpecum, C. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106556
Non-alcoholic fatty liver disease is associated with a higher risk of erectile dysfunction than alcoholic fatty liver disease
Chan, H.-B., Su, S., Lee, C., & Hsu, C.-Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1625498
Modeling the progression of NAFLD: a multi-state Markov approach based on BMI classification in the Chinese population
Tang, J., Halengbieke, A., Tong, C., Ni, X., Cao, T., Han, Y., Chen, S., Kong, L., & Yang, X. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101448
Metabolic associated steatotic liver disease in Qatar: Analysis of dietary patterns and nutrient intake
Alalwani, J., Derbala, M. F. M., Tayyem, R., & Bassil, M. S. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i11.111995
Highlighting the relevance of a multidisciplinary approach in metabolic-asociated steatotic liver disease (MASLD)
Lara‐Romero, C., Fernández-Gómez, M. A., Martı́n, F., Castilla‐Guerra, L., Funuyet‐Salas, J., Berná, G., Millán-Domínguez, R., & Romero‐Gómez, M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2584022
“Given the high and rising prevalence of MASLD (from ~25% in 2016 to > 30% today) [10], early identification of patients with significant fibrosis who may benefit from hepatology referral is a key challenge.”
Differential Risk of Obstructive Sleep Apnea in Alcoholic Versus Non-Alcoholic Fatty Liver Disease: A Propensity-Matched Cohort Study
Chang, L.-H., Lin, H.-C., Hsieh, W.-C., & Hsu, C.-Y. (2025) · Medicina · doi:10.3390/medicina61122146
“A large meta-analysis including over 1.2 million individuals reported an incidence of 46.1 per 1000 person-years, with higher risk observed in males, smokers, and overweight or obese individuals [7].”
Influential
Additional file 1 of Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study
Zhou, B.-G., Xia, J., Jiang, X., Ding, Y.-B., & She, Q. (2024) · Figshare · doi:10.6084/m9.figshare.25440968
Metabolite clusters linking fatty liver disease to cardiovascular mortality in coronary heart disease patients
Heerkens, L., Gonzales, G. B., Geleijnse, J. M., & van Duijnhoven, F. J. B. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104535
Targeting cancer stem cells enhances multikinase inhibitor therapy in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma
Pan, Y., Zhang, X., Wong, C. C., Chen, H., Stephanie, M., Lee, T. K., Yuan, K., Liang, C., Zhou, X., Lau, H. C.-H., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-336527 · Cited by 2
Computational-experimental study reveals direct target and bioactives of Ajania fruticulosa against NAFLD via TLR2/NF-κB/PPAR-γ signaling
Chen, C., Ma, L., Dawuti, A., Feng, X., Chen, S., An, X., Bai, Y., Zhang, T., Aydin, M., kashmiri, K., et al. (2026) · npj Science of Food · doi:10.1038/s41538-026-00722-w
Xanthine oxidoreductase activity in MASLD: links to lipid metabolism, oxidative stress, and inflammation
Cen, Y., Pu, Z.-Y., Zi, X., Peng, S., Liu, R., Yang, B., Fan, Y.-N., Yang, J., Zhao, Y., & Zhang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1731772
“Over recent years, MASLD has become a signi ﬁ cant global public health challenge with rising prevalence worldwide (4).”
Preclinical Models of Metabolic Dysfunction–Associated Steatotic Liver Disease for Therapeutic Testing
Cutrone, A. M., Yeh, H., Uygun, K., & Usta, O. B. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-081325-053420
Integrated lifestyle management to mitigate MASLD risk in patients with chronic kidney disease: a prospective cohort study
Yan, C., Shen, X., Han, S., He, J., Wang, T., Gong, X., & Petersen, J. D. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07901-z
“Metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) have emerged as major global public health challenges, with an estimated prevalence of approxiately32% and 15% among the adult population, respectively [1, 2].”
Association Between Asymmetric Dimethylarginine, Its Change, and Subclinical Carotid Atherosclerosis in Metabolic Dysfunction–Associated Steatotic Liver Disease
Wang, W., Ren, X. T., Sun, P., Lyu, T. T., Wang, Y., Tan, Y. F., Zhao, X. Y., & Li, M. (2026) · Journal of Digestive Diseases · doi:10.1111/1751-2980.70045
MAST versus FAST for active fibrotic MASH: a meta-analysis supporting risk-stratified diagnostic pathways
Liu, S., Zhang, Q., Wang, L., Tang, Q., & Hu, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1779292
“Globally, MASLD affects approximately 25–30% of the general population (equivalent to more than 1 billion people) (6), of whom 20% will progress to MASH.”
Effects of Internet‐Based Lifestyle Interventions on Nonalcoholic Fatty Liver Disease: A Meta‐Analysis of Randomized Controlled Trials
Wang, C., Song, Y., Wu, J., & Mei, H. (2026) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/cjgh/5125598
“Furthermore, the incidence of NAFLD is higher than in non-China regions [3], and it has surpassed viral hepatitis to become the predominant liver disease in China.”
Association between the aMAP risk score and mortality in the MASLD/MetALD/ALD patient population: a cohort study
Li, P.-Y., Mo, Y., Fu, R.-B., Song, J., Kuang, S.-L., Zhao, Y., Jiang, W., & Dong, X.-F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1799986
FLAG: Fatty Liver Awareness Game for Liver Health Literacy in Last-Semester Software Engineering Students
Parrales–Bravo, F., Borbor-Albay, J., Jadán-Guerrero, J. L., & Vasquez-Cevallos, L. (2026) · Multimodal Technologies and Interaction · doi:10.3390/mti10050048
Endothelial cell glycogen synthase kinase 3β promotes lipotoxic endotheliopathy and liver inflammation in MASH
Sano, A., Guo, Q., Warasnhe, K., Meroueh, C., Satthawiwat, N., Hamdi, A., Hmaydoosh, G., 戴新, Yaqoob, U., Pavelko, K. D., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.202552
“Metabolic dysfunction–associated steatohepatitis (MASH) is a growing public health problem worldwide (1–3).”
Tetrandrine, a Major Alkaloid From Stephaniae Tetrandrae Radix , Ameliorates Non‐Alcoholic Fatty Liver Disease in Zebrafish via the PI3K / AKT / STAT3 Pathway
Sun, P., Wu, J., Ma, K., Wei, X., Ma, J. J., Han, W., Zhu, X., Zhang, X., Wang, X., Tuersunniyazi, T., et al. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71814
Global trends, epidemiological patterns, and disability burden of metabolic dysfunction-associated steatotic liver disease–related cirrhosis from 1990 to 2021: A comprehensive analysis of the Global Burden of Disease study
Xuli, W., & Wang, B. Q. (2026) · Journal of International Medical Research · doi:10.1177/03000605261446157
“1,2 It encompasses a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and ultimately hepatocellular carcinoma.”
Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition
Brendel, J. M., Mayrhofer, T., Kerkovits, N. M., Kolossváry, M., Ersözlü, S., Alhanti, B., Corey, K. E., Pagidipati, N., Shah, S. H., Meyersohn, N. M., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.022
A prospective, randomized, controlled, open-label blinded end point clinical study of Ayulite in comparison with vitamin E for efficacy and safety in patients with non-alcoholic fatty liver disease
Shivane, V. K., Tamoli, S., Hartalkar, A., Gajre, K., Shah, H., Mandot, A., Padalkar, S., Barnabas, R., & Padalkar, S. (2026) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2026.101341
“Also, there was 3-fold increase in the incidence rate of NAFLD between 2000 and 2015 [4].”
A fluorescence-based high-content imaging workflow for multi-parametric lipid droplet phenotyping via Oil Red O fluorescence
Yan, S., Yao, Y., Liu, C., Zhu, H., Wu, X., Lyu, C., & Yangyang (2026) · Methods · doi:10.1016/j.ymeth.2026.06.002
Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study
Khalil, I., Sarker, P., Hossain, M. S., Chowdhury, A., Khalid, A. A., Saha, A., Chowdhury, J., Akter, M. M., Promi, S. A., Sayed, M. A., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.06.004
Karnofsky Performance Status Is Associated with Patient and Graft Survival After Liver Retransplantation
Thuluvath, A. J., Zhang, H., Yerneni, S., & Verna, E. C. (2026) · Transplantation Proceedings · doi:10.1016/j.transproceed.2026.06.017
Efficacy of tirzepatide versus SGLT2 inhibitors in metabolic dysfunction-associated steatotic liver disease (MASLD): a multicenter propensity-matched real-world study
Khalil, I., Sarker, P., Nur, N., Hossain, M. S., Khalid, A. A., Al-Badri, S. G., Akter, M. M., Das, M., & Rahman, M. T. (2026) · Hepatology International · doi:10.1007/s12072-026-11122-3
A Growing Mortality Divide: Demographic and Regional Disparities in Cirrhosis With Renal Failure, U.S. 1999–2023
Faheem, M. S. B., Najmi, O. E. M., Ahmad, U., Yahya, A., Maheshwari, S., Arif, U., & Mal, M. (2026) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-026-01952-6
Burden and trends of alcohol- and NAFLD/NASH-related liver disease in 5 East Asian countries: A GBD 2021 analysis
Liang, B., Shi, H., Tie, X., Zeng, Q., & Long, K. (2026) · Medicine · doi:10.1097/md.0000000000049944
Disentangling the hepatic risks of familial Mediterranean Fever and colchicine: A propensity score-matched analysis of 19,231 patients
Gilad, L., Lidar, M., Ben‐Zvi, I., Davidov, Y., Zigmond, E., & Druyan, A. (2026) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2026.153045
Global burden of cirrhosis and hepatocellular carcinoma attributable to metabolic dysfunction-associated steatohepatitis in young and middle-aged adultsPreprint
Shen, X., Yan, C., & Gong, X. (2026) · Research Square · doi:10.21203/rs.3.rs-10175659/v1
Non-lean versus lean MASLD: associations with advanced cardiovascular-kidney-metabolic syndrome in adults with type 2 diabetes mellitus, a cross-sectional study
Wang, J.-W., Jiang, L., Lin-lin, G., Ren, J., Zhao, S.-Y., Qiao, Y.-N., & Liu, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1910398
Progress in extraction, purification, chemical structure, bioactivities, and food preservation applications of polysaccharides from Portulaca oleracea L.
Sun, S., Meng, K., Zhang, Q., & Zhang, J. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122317
Pathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum
Zhao, Z., & Hu, X. (2026) · Biomedicines · doi:10.3390/biomedicines14091884
Deciphering the polypharmacology of a traditional Chinese formula for MASLD: Network proximity to identifying Akt-modulating active ingredients
Zhang, Z., Wang, M., Yang, W., Li, S., Cai, Y., Chen, J., Chen, X., Gu, M., & Gu, Y. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122349
Soyasaponin A1 ameliorates metabolic dysfunction-associated steatohepatitis via potentially reinforcing hepatoprotective capacity of Akkermansia muciniphila, restoring intestinal barrier homeostasis, and putatively modulating wnt/β-catenin signaling pathway
Qin, Z., Guo, Q., Zhang, K., Lu, J., Wang, J., Li, Z., Zhong, L., Huang, Y., Li, Q., Zheng, X., et al. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.109870
DualSS: A Dual‐Diffusion Synthetic Sampling Framework for Screening Fatty Liver Severity With Class‐Imbalanced Tongue Images
Chen, T., Gao, J., Xu, Y. N., Qiu, W., Liu, K., Wu, Y., & Ye, W. (2026) · CAAI Transactions on Intelligence Technology · doi:10.1049/cit2.70174
Research Progress in the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease
蒋, 春. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1693194
Association between body composition and metabolic dysfunction-associated steatotic liver disease in Chinese general population: a cross-sectional study stratified by sex and obesity status
Tan, X., Hou, X., Wen, Y., Huang, Y., & Qin, S. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1921631
Machine learning-based discrimination of metabolic dysfunction-associated steatotic liver disease: implications of tryptophan metabolites as potential biomarkers
刘珍妮, Li, S., Tan, Y., Li, B., Qin, N., Liu, P., Li, F., Chen, Z., Li, Z., Lyu, X., et al. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.122854
Improving MASLD Identification in Patients with T2D: A Computable Phenotype Framework Integrating Structured Data and Clinical NotesPreprint
Chen, Y., Sharma, A., Yang, Q., Chen, Y., & Yin, R. (2026) · medRxiv · doi:10.64898/2026.09.26.26364078
Alcohol Liver Pathology Signature: A Composite Histological Pattern for Differentiating Alcohol–associated Liver Disease from Metabolic Dysfunction–associated Steatotic Liver Disease
Xue, Y., Hwaung, P., Li, Y., Khambu, B., Yan, S., & Yin, X.-M. (2026) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2026.00017
Association of Noise Exposure, Perceived Noise Impact, and BMI on Nonalcoholic Fatty Liver Disease Among Chinese Seafarers: Nationwide Population-Based Survey
Shi, R., Zhou, S., Yang, Z., Chen, E., Shang, H., & Zhou, Y. (2026) · JMIR Public Health and Surveillance · doi:10.2196/57844
“Nonalcoholic fatty liver disease (NAFLD) has emerged as a critical global public health challenge among chronic noncommunicable diseases [1].”
Fatty liver disease: contribution of the introduction of new nomenclature into clinical practice
Aliyev, S., Hidayatov, A., & Aliyev, E. (2026) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2026-104-7-513-520
Long‐Term Exercise Training for Liver Enzymes and Liver Fat in Adults With Nonalcoholic Fatty Liver Disease: A Multilevel Dose–Response Meta‐Analysis
Li, D., Cui, Y., & Li, Z. (2026) · Obesity Reviews · doi:10.1111/obr.70250
Metabolic Dysfunction‐Associated Steatotic Liver Disease
Kanwal, F., & Wong, V. W. S. (2026) · Wiley eBooks · doi:10.1002/9781394360031.ch31
Metabolic dysfunction associated chronic liver disease in Europe: much has to be done before we are really united
Ciaula, A. D., van Dijk, A. M., Portincasa, P., & van Erpecum, K. J. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107198

Authors: Le, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., Cheung, R., & Nguyen, M. H.
Affiliations: University of Vermont (US)
Burrell College of Osteopathic Medicine (US)
Third Affiliated Hospital of Sun Yat-sen University (CN)
Nagoya University (JP)
Stanford Medicine (US)
Stanford University (US)
VA Palo Alto Health Care System (US)
Corresponding author: Nguyen, Mindie H.
ORCID: Le, Michael H.
Wu, Yuankai
Ito, Takanori
Lee, KeeSeok
Stave, Christopher D.
Henry, Linda
Barnett, Scott D.
Cheung, Ramsey
Nguyen, Mindie H.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2023-08
Volume: 79
Issue: 2
Pages: 287-295
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2023.03.040
OpenAlex: W4362719751
Cited by: 303
References: 51
Citations by year: 2026: 71 · 2025: 98 · 2024: 98 · 2023: 35
FWCI: 11.80
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords: NAFLD incidence, global prevalence, ultrasonography, obesity, overweight, smoking, sex differences, China, South Korea, Japan, cohort studies, risk factors, study quality bias, study design bias, publication bias
MeSH terms: Adult, Female, Humans, Male, Obesity, Cohort Studies, Incidence, Overweight, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks